|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study aimed to examine the association between CRP gene polymorphism and clinical and laboratory findings in ankylosing spondylitis (AS) patients.
|
26480896 |
2016 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
C1M, C3M, and C4M2 were associated with ASDAS-CRP in AS and nr-axSpA after adjustment for age, gender, and disease duration.
|
31375691 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
They were also more likely to have moderate/severe psoriasis (body surface area ≥ 3%, 42.5% vs 31.5%) and significantly worse disease as measured by a lower prevalence of minimal disease activity (30.1% vs 46.2%) and higher nail psoriasis scores [visual analog scale (VAS) 11.4 vs 6.5], enthesitis counts (5.1 vs 3.4), Bath Ankylosing Spondylitis Disease Activity Index (4.7 vs 3.5) scores, Bath Ankylosing Spondylitis Functional Index (3.8 vs 2.5) scores, C-reactive protein levels (4.1 vs 2.4 mg/l), and scores for physical function (Health Assessment Questionnaire, 0.9 vs 0.6), pain (VAS, 47.7 vs 36.2), and fatigue (VAS, 50.2 vs 38.6).
|
29961691 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We sought to determine the association between elevated CRP levels and AS diagnosis in a prospective community-based study of 129,681 Chinese adults over a follow-up period of 8 years.
|
30768617 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exercise habits and C-reactive protein may predict development of spinal immobility in patients with ankylosing spondylitis.
|
30022369 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
PBMCs (p=0.047) and T cells (p=0.035) SOCS1 decreased significantly in the AS subgroup with lower CRP than controls.
|
26812031 |
2016 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baseline characteristics were similar regarding C-reactive protein, but differed for other variables, including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (range 3.5-6.3) and Ankylosing Spondylitis Disease Activity Score (ASDAS) (2.7-3.8) (both p < 0.0001).
|
30070923 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the validity of Assessment in Spondyloarthritis International Society (ASAS) endorsed Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive protein (-CRP) and ASDAS erythrocyte sedimentation rate (-ESR) in axial spondyloarthritis (axSpA) and to estimate the cut-off values for male and female patients with axSpA.
|
27309497 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Similarly, the strong associations between the cytokines or between IL-12 and ESR or CRP were observed in HLA-B27-positive AS patients.
|
17459079 |
2007 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The factors of stages (P = 0.002), HLA-B27 (P = 0.002), ESR (P = 0.001) and C-reactive protein (P = 0.000) were considered to be related to the expression of SP selectin, which indicated that SP-selectin might be involved in the development of AS.
|
26261626 |
2015 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The observations that CTLA-4 +49A>G genotypes are associated with circulatory CRP levels and significantly less AS subjects carrying CTLA-4 higher-secretor -318 T allele suggest the level and regulation of inflammation in AS subjects may be pre-determined by and associated with CTLA-4 genotypes.
|
20030788 |
2010 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In AS, JAK-1 expression in PB cells rather than ESR or CRP might be regarded as a bio-marker for monitoring disease activity and functional index in AS.
|
29530480 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Metrology Index, Bath Ankylosing Spondylitis Functional Index scores, erythrocyte sedimentation rate, C-reactive protein, glycemia, total cholesterol, and triglyceride levels were also recorded.Patients with AS showed significantly lower values of mean and maximum IMT at the level of the common carotid (P = .02 and .04, respectively) and the carotid bulb (P = .0006 and .0005, respectively) compared to those of healthy controls.
|
29979389 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Fewer patients with increased C-reactive protein levels, less extensive structural damage, slower radiographic progression, and significantly lower Bath AS Metrology and Bath AS Functional Indices were reported for nr-axSpA than for AS.
|
27855973 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were no significant differences in BMD between AS patients with elevated CRP and the patients with normal CRP and PLT.
|
31851643 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe three mother-daughter couples concordant for AS and HLA-B27, both treated with TNF-α inhibitors, for whom the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP were evaluated during a follow-up of 24 months.
|
25962691 |
2015 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AS Disease Activity Scores and CRP levels were significantly higher in patients with AS compared with nr-axSpA (2.4 (IQR 1.7-2.8) vs 2.0 (IQR 1.1-2.3), p=0.022 and 7.1 (IQR 2.6-14.9) vs 2.5 (IQR 0.8-8.2) mg/L, p<0.001, respectively).
|
30944131 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, M-MDSC levels correlated positively with the clinical index of AS, including the Bath ankylosing spondylitis disease activity index (BASDAI) score, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels.
|
30075733 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Disease activity indexes included Bath ankylosing spondylitis disease activity index (BASDAI), erythrocyte sediment rate (ESR), C-reactive protein (CRP), and ankylosing spondylitis disease activity score (ASDAS).
|
27919202 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion:</b> The available evidence suggests that NSAIDs are unable to delay radiographic progression of AS even in patients with elevated CRP levels.
|
31637243 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Bath AS Function Index and Bath AS Disease Activity Index were assessed in AS patients and levels of erythrocyte sedimentation rate and C-reactive protein were measured in AS and healthy groups.
|
29067128 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To analyze the alteration of lipid profile and inflammatory markers in the serum of patients with gouty arthritis (GA), the levels of serum lipid profile, C-reactive protein (CRP), and erythrocyte sedimentation rates (ESRs) were measured in the serum of 69 gout patients, 35 patients with rheumatoid arthritis (RA), 23 patients with ankylosing spondylitis (AS)/spondyloarthropathy (SpA), and 25 patients with osteoarthritis (OA).
|
28445313 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with the carriers of G/G genotype, remarkably elevated erythrocyte sedimentation rate and serum C-reactive protein were observed in AS patients with G/A variant (87.06±49.40 vs. 55.53±42.99mm/h, P=.0126; 54.95±27.77 vs. 34.36±36.13mg/dl, P=.0116, respectively), and they always presented with inflammatory spinal pain (70.00% vs. 43.33%, P=0.0214) and suffered relatively mild sacroiliitis (65.00% vs. 41.67%, P=0.0431).
|
28610765 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum retinol levels did not correlate with indices of disease activity defined serologically (C-reactive protein, erythrocyte sedimentation rate) or clinically (Bath AS Disease Activity Index, Bath AS Functional Index).
|
18050373 |
2007 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All disease activity parameters-the ankylosing spondylitis disease activity scale, the C-reactive protein, the erythrocyte sedimentation rate, and the bath ankylosing spondylitis disease activity index-decreased significantly (p < 0.001).
|
30690799 |
2019 |